Research Article

The association between hypoxia, chronic ischemia and alters prostate structure and progress of chronic prostatic disease

Mauro Luisetto*, Behzad Nili Ahmadabadi, Ghulam Rasool Mashori, Gamal Abdul Hamid

Published: 09/20/2019 | Volume 3 – Issue 1 | Pages: 042-078

Abstract

Chronic prostatitis today show high level of relapses and recurrent pathological events even if using the best pharmacological therapy. A better understanding of physiopathological effect of ischemic hypoxic condition (pelvic, prostate tissue) and the lymphatic congestion in same body region contribute in evolution of a complex condition. The same focusing the strategy in biofilm reduction or in leukocyte infiltration can be a right way to reduce relapses and progression of the prostatic disease. Hypoxia is also related to prostatic cancer progression and prostatic biofilm if responsible of making a new micro- environment often drug resistance. A deep knowledge in this kind of phenomena can improve the clinical effect of drug therapy.

Read Full Article HTMLDOI: 10.29328/journal.apps.1001016Cite this Article

References

  1. Kogan MI, Matsionis AE, Belousov II, Povilaitite PE. Morphological evidence of the ischemic nature of the prostatic fibrosis in the classical chronic pelvic pain syndrome / IIIB chronic prostatitis. Urologiia. 2018; 3: 12-19. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30035413
  2. Vaidyanathan R, Vibhash C. Mishra. Chronic prostatitis: Current concepts. Indian J Urol. 2008; 24: 22-27. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19468353
  3. Well-Being, Money SA. Therapeutic Devices Should be implemented in the Healthcare System for the Treatment of Chronic Noncancerous Prostate and Kidney Diseases Saving People’s. Ann Mil Health Sci Res. 2018; 16: e81033.
  4. Kogan MI, Belousov II, Bolotskov AS. Arterial blood flow in the prostate in the syndrome of chronic pelvic pain/chronic prostatitis. Urologiia. 2011; 3: 22-28. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21874666
  5. Kim HJ, Park JW, Cho YS, Cho CH, Kim JS, et al. Pathogenic role of HIF-1? in prostate hyperplasia in the presence of chronic inflammation. Biochim Biophys Acta. 2013; 1832: 183-194. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22986049
  6. Portia T, Jing-Hua Y, Yedan Li, Lori BL, Kazem M.  Structural modifications of the prostate in hypoxia, oxidative stress, and chronic ischemia. Korean J Urol. 2015; 56: 187-196. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25763122
  7. Kimio S, Saori N, Katsumi K, Katsuhiro A, Tomoyuki U, et al. Laboratory investigation Pelvic venous congestion with castration causes chronic prostatitisin rats.  Int J Urol. 2016; 23: 431-435.
  8. Timothy J Coker, Daniel M Dierfeldt. Acute Bacterial Prostatitis: Diagnosis and Management. Am Fam Physician. 2016; 93: 114-120. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26926407
  9. Shazia R Chaudhry, Khalid Chaudhry. Anatomy, Abdomen and Pelvis. Pelvis. 2019.
  10. Chiappino G, Pisani E. Prostate diseases of occupational origin. Med Lav. 2002; 93: 67-72. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12087801
  11. Konstantinos S, Vittorio M, Gianpaolo P, Nektaria R, Richard L, et al. Gram-positive microorganisms isolated during Chronic Bacterial Prostatitis investigation. Hellenic Urology. 2019; 30: 35-49.
  12. Azadzoi KM, Babayan RK, Kozlowski R, Siroky MB. Chronic Ischemia Increases Prostatic Smooth Muscle Contraction in the Rabbit. J Urol. 2003; 170: 659-663. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12853851
  13. Berger AP, Deibl M, Leonhartsberger N, Bektic J, Horninger W, et al.  Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int. 2005; 96: 1073-1078.             PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16225531
  14. Chen X, Hu C, Peng Y, Lu J, Yang NQ, et al. Association of diet and lifestyle with chronic prostatitis/chronic pelvic pain syndrome and pain severity: a case-control study. Prostate Cancer Prostatic Dis. 2016; 19: 92-99. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26666410
  15. Andrew PB, Michel P, Richard EB, Dean AT. Management of Men Diagnosed With Chronic Prostatitis/Chronic Pelvic Pain Syndrome Who Have Failed Traditional Management. Rev Urol. 2007; 9: 63-72. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1892625/
  16. Gao DJ, Guo YS, Yu HY, Wang YJ, Cui WG. Prevalence and related factors of prostatitis-like symptoms in young men; Zhonghua Nan Ke Xue. 2007; 13: 1087-1090. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18284056
  17. Taylor BC, Noorbaloochi S, McNaughton-Collins M, Saigal CS, Sohn MW, et al. Excessive Antibiotic Utilization in Men with Prostatitis. Am J Med. 2008; 121: 444-449. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18456041
  18. Jinjin MA, Gharaee-Kermani M, Lakshmi K, John MH, Jeremy A, et al. Prostatic Fibrosis is Associated with Lower Urinary Tract Symptoms. J Urol. 2012; 188: 1375-1381. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22906651
  19. Niemitz C. The evolution of the upright posture and gait-a review and a new synthesis. Naturwissenschaften. 2010; 97: 241-263.     PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20127307
  20. Ran Z, Andrea KC, Jordan DD, Edward LG, Walter CW, et al. Physical Activity and Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Med Sci Sports Exerc. 2015; 47: 757-764. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25116086
  21. Dikov D, Bachurska S, Staikov D, Sarafian V. Intraepithelial lymphocytes in relation to NIH category IV prostatitis in autopsy prostate. Prostate. 2015; 75: 1074-1084. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25917232
  22. Anim JT, Udo C, John B. Characterisation of inflammatory cells in benign prostatic hyperplasia. Acta Histochem. 1998; 100: 439-449. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9842422
  23. Pavone C, Caldarera E, Liberti P, Miceli V, Di Trapani D.  Prostate Diseases Correlation between Chronic Prostatitis Syndrome and Pelvic Venous Disease; A Survey of 2,554 Urologic Outpatients. European Urology. 37: 400-403.
  24. Luisetto M, Naseer A, Ghulam RM, Ahmed YR, Farhan AK, et al. Endogenous Archeological Sciences: Anatomy, Physiology, Neuroscience, Biochemistry, Immunology, Pharmacology, Oncology, Genetics as Instrument for A New Field of Investigation? Modern Global Aspects for a New Discipline Open Access J Addict & Psychol. 2018; 1.
  25. Levine JA. Sick of sitting. Diabetologia. 2015; 58: 1751-1758.
  26. Hadi D, Alireza C, Haleh G, Mehran K. Adverse Effects of Prolonged Sitting Behavior on the General Health of Office Workers. J Lifestyle Med. 2017; 7: 69-75. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29026727
  27. Loran OB, Dunaevski I, Vishnevski AE, Vashkevich VI. The joint use of hyperbaric oxygenation and EHF therapy in benign prostatic hyperplasia and its combination with chronic prostatitis. Urol Nefrol (Mosk). 1997; 2: 32-34. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9206881
  28. Motoaki S, Panagiota T, Ryo O, Shogo S, Masashi H, et al. Prostatic ischemia induces ventral prostatic hyperplasia in the SHR; possible mechanism of development of BPH. Asian J Urol. 2017; 4: 158-163.
  29. Motoaki S, Panagiota T, Shogo S, Takehiro S, Yukako K, et al. Prostatic ischemia induces ventral prostatic hyperplasia in the SHR; possible mechanism of development of BPH. Sci Rep. 2014; 4: 3822. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24448152
  30. Jason G, Omar S, Noel LS, Gunjan J, Sohrab V, et al. Clinical utility of hyperbaric oxygen therapy in genitourinary medicine. Med Gas Res. 2018; 8: 29-33. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29770194
  31. Declan J McKenna, Rachel E, Klaus P. Current challenges and opportunities in treating hypoxic prostate tumors. J Cancer Metastasis Treat. 2018; 4:11.
  32. Ficarra V. Editor’s Choice is chronic prostatic inflammation a new target in the medical therapy of lower urinary tract symptoms (LUTS) due to benign prostate hyperplasia (BPH)? BJU International. 2013; 112: 421-422. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23879899
  33. Andrzej G, Joczyk-Matysiak E, Marzanna S, Ryszard M, et al. Phage Therapy in Prostatitis: Recent prospects. Front Microbiol. 2018; 9: 1434. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30008710
  34. Bartoletti R, Cai T, Nesi G, Albanese S, Meacci F, et al . The impact of biofilm-producing bacteria on chronic bacterial prostatitis treatment: results from a longitudinal cohort study. World J Urol. 2014; 32: 737-742. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23918259
  35. Corvec S, Furustrand Tafin U, Betrisey B, Borens O, Trampuz A. Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-?-lactamase-producing Escherichia coli in a foreign-body infection model.  Antimicrob Agents Chemother. 2013; 57: 1421-1427. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23295934
  36. David L, Jean-Marc G. Biofilm-Related Infections: Bridging the Gap between Clinical Management and Fundamental Aspects of Recalcitrance toward Antibiotics. Microbiol Mol Biol Rev. 2014; 78: 510-543. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25184564
  37. Muhamad AB, Judy McKimm, Seraj Zohurul H, Anwarul AM, Mainul H. Chronic tonsillitis and biofilms: a brief overview of treatment modalities. J Inflammation Res. 2018; 11: 329-337.         PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30233227
  38. Batoni G, Maisetta G, Esin S. Antimicrobial peptides and their interaction with biofilms of medically relevant bacteria. Biochim Biophys Acta. 2016; 1858: 1044-1060. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26525663
  39. Hogan S, O’Gara JP, O’Neill E. Novel Treatment of Staphylococcus aureus Device-Related Infections Using Fibrinolytic Agents. Antimicrob Agents Chemother. 2018; 62. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29203484
  40. Zapotoczna M, McCarthy H, Rudkin JK, O’Gara JP, O’Neill E. Coagulase in Staphylococcus aureus Biofilm Development Reveals New Therapeutic Possibilities for Device-Related. J Infect Dis. 2015; 212: 1883-1893. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26044292
  41. De Almeida J, Hoogenkamp M, Felippe WT, Crielaard W, van der Waal SV. Effectiveness of EDTA and Modified Salt Solution to Detach and Kill Cells from Enterococcus faecalis Biofilm. J Endod. 2016; 42: 320-323. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26723483
  42. Choi YS, Kim C, Moon JH, Lee JY. Removal and killing of multispecies endodontic biofilms by N-acetylcysteine. Braz J Microbiol. 2018; 49: 184-188. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28916389
  43. Dinicola S, De Grazia S, Carlomagno G, Pintucci JP. N-acetylcysteine as powerful molecule to destroy bacterial biofilms. A systematic review. Eur Rev Med Pharmacol Sci. 2014; 18: 2942-2948. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25339490
  44. Ham Y, Kim TJ. Inhibitory activity of monoacylglycerols on biofilm formation in Aeromonas hydrophila, Streptococcus mutans, Xanthomonas oryzae, and Yersinia enterocolitica. Springerplus. 2016; 5: 1526. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27652099
  45. Richter K, Facal P, Thomas N, Vandecandelaere I, Ramezanpour M, et al. Taking the Silver Bullet Colloidal Silver Particles for the Topical Treatment of Biofilm-Related Infections; Taking the Silver Bullet Colloidal Silver Particles for the Topical Treatment of Biofilm-Related Infections. ACS Appl Mater Interfaces. 2017; 9: 21631-21638. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28598149
  46. Gujie Mi, Di Shi, Mian Wang, Thomas J. Webster Adv.  Reducing Bacterial Infections and Biofilm Formation Using Nanoparticles and Nanostructured Antibacterial Surfaces. Healthcare Mater. 2018; 7.
  47. Sousa C, Botelho C, Oliveira R. Nanotechnology applied to medical biofilms control. communicating current research and technological advances A. Méndez-Vilas (Ed.). 2011.
  48. Soto SM.  Biofilms in Urinary Tract Infections: New Therapeutic Approaches. Advances in Biology. 2014.
  49. Braj RS, Brahma NS, Akanksha S, Wasi Khan, Alim HN, et al. Mycofabricated biosilver nanoparticles interrupt Pseudomonas aeruginosa quorum sensing systems. Sci Rep. 2015; 5: 13719. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26347993
  50. Kaiser SJ, Mutters NT, Blessing B, Günther F. Natural isothiocyanates express antimicrobial activity against developing and mature biofilms of Pseudomonas aeruginosa. Fitoterapia. 2017; 119: 57-63. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28390975
  51. Fu B, Wu Q, Dang M, Bai D, Guo Q, et al. Inhibition of Pseudomonas aeruginosa Biofilm Formation by Traditional Chinese Medicinal Herb Herba patriniae. Biomed Res Int. 2017; 2017: 9584703. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28377931
  52. Kumar L, Chhibber S, Kumar R, Kumar M, Harjai K. Zingerone silences quorum sensing and attenuates virulence of Pseudomonas aeruginosa. Fitoterapia. 2015; 102: 84-95. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25704369
  53. Farias KS, Kato NN, Boaretto AG, Weber JI, Brust FR, et al. Nectandra as a renewable source for (+)-?-bisabolol, an antibiofilm and anti-Trichomonas vaginalis compound. Fitoterapia. 2019; 136: 104179. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31121252
  54. Tse-Kai Fu, Sim-Kun Ng, Yi-En Chen, Yuan-Chuan Lee, Fruzsina Demeter, et al. Rhamnose Binding Protein as an Anti-Bacterial Agent-Targeting Biofilm of Pseudomonas aeruginosa. Mar Drugs. 2019; 17. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31207891
  55. Lokender K, Christopher RC, Susanta KM. Metalloprotease-1 inhibits and disrupts Enterococcus faecalis biofilms. Sarkar PLoS One. 2019; 14.
  56. Yucui L, Yanjie Xu, Qiuhang S, Fei W, Luguo S, et al. Anti-biofilm Activities from Bergenia crassifolia Leaves against Streptococcus mutans. Front Microbiol. 2017; 8: 1738. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601420
  57. Deep G, Panigrahi GK. Hypoxia-Induced Signaling Promotes Prostate Cancer Progression: Exosomes Role as Messenger of Hypoxic Response in Tumor Microenvironment. Crit Rev Oncog. 2015; 20: 419-434. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27279239
  58. Massimo A, Shabnam S, Youngjin K, Christina AM Jamieson. Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts, and Michael Karin. PNAS. 2014; 111: 14776-14781.             PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4205637
  59. Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell. 2005; 9: 617-628. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16256737
  60. Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2011; 4: 486-450. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21233290
  61. Stark T, Livas L, Natasha K. Inflammation in prostate cancer progression and therapeutic targeting. Transl Androl Urol. 2015; 4: 455-463. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26816843
  62. Danielle SB, Hyun Koo. Targeted, triggered drug delivery to tumor and biofilm micro environment. Nano Medicine (Lond). 2016; 11: 873-879. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26987892
  63. Guillaume L, Luis Estévez-Salmeron, Steve Oh, David L, Beverly ME, et al. An analogy between the evolution of drug resistance in bacterial communities and malignant tissues. Nat Rev Cancer. 2011; 11: 375-382. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21508974
  64. Kresser. How to Treat Biofilms. 2018